ArticleCureus2026
Prognostic Value of Frailty and Other Risk Factors in Patients Undergoing Lower Limb Revascularisation or Primary Major Lower Limb Amputation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives Patients requiring revascularisation are increasingly becoming older, more comorbid, and deconditioned. Frailty is associated with adverse outcomes, but its role in patients undergoing revascularisation remains underexplored. The study aimed to examine the role of frailty in amputation rates, amputation-free survival and all-cause mortality. Method Patients aged ≥ 18years in a tertiary centre in the United Kingdom, who underwent open revascularisation, and primary amputation between September 2022 and May 2024. Electronic clinical records till January 2025 were reviewed, collated and analysed. Frailty was assessed preoperatively by anaesthetists using the Rockwood Clinical Frailty Scale (CFS), and a score was assigned Results Four hundred and seven patients underwent revascularisation, and 89 had primary amputation. In the revascularisation group, 55 deaths (13.5%) and 46 (11.3%) major amputations occurred. CFS ≥ 6 was present in 116 (29%) patients who underwent revascularisation and independently predicted both amputation (HR 3.13, 95% CI 1.62-6.06, p<0.001) and all-cause mortality (HR 1.27, 95% CI 1.04-1.55, p=0.017). Diabetes also increased amputation risk (HR 2.93, 95% CI 1.51-5.67, p=0.001). In the primary amputation group, mortality was associated with age and diabetes, but not with frailty. However, patients with CFS ≥ 6 died earlier (p < 0.023). Conclusion Frailty plays an important role in predicting outcomes. Patients with higher frailty scores were significantly more likely to experience major amputation or death, particularly within the first year after their procedure. This early postoperative period appears to be a key window, during which frail patients may benefit from closer monitoring and support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.